glp 1 and mash Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual triple agonists GLP-1 therapies: a new frontier

Weekly injections tend to show faster and more consistent weight loss results compared to oral formulations because injectable medications bypass digestive breakdown and achieve higher bioavailability

Peptide therapy may be appropriate for individuals experiencing fatigue, weight gain, slow recovery, hormonal imbalance, sleep disruption, joint or muscle discomfort, or age-related changes in skin, metabolism, or cognition

GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow

Meta-analyses of randomised controlled trials have demonstrated mean increases of approximately 24 beats per minute, with variation depending on the specific agent, dose, and patient population